When a sponsor is based in a country of concern, the signing question is no longer only budget and timeline.
November 19, 2026
5
min read
By
Julio G. Martinez-Clark, CEO, bioaccess®
A site leader raised this in the Society for Clinical Research Sites (SCRS) community this week: how is Executive Order (EO) 14117 affecting clinical trials with sponsors based in China? It is the right question, and it is arriving at the wrong moment at most sites — after feasibility, sometimes after the budget is signed, when the data questions are hardest to renegotiate. I run Amavita Research Services, a Miami cardiovascular trial site, and bioaccess®, a first-in-human (FIH) contract research organization (CRO) running trials anywhere from Canada down to Argentina. On both sides of the table, the pattern that works is the same: treat the data-flow review as part of signing, not as an afterthought.
What EO 14117 actually changed
EO 14117, signed on February 28, 2024, addresses access by countries of concern to Americans' bulk sensitive personal data and United States government-related data. The Department of Justice (DOJ) implemented it through its Data Security Program (DSP), codified at Title 28 of the Code of Federal Regulations (CFR), Part 202, which took effect on April 8, 2025. The countries of concern are China (including Hong Kong and Macau), Cuba, Iran, North Korea, Russia, and Venezuela.
The rule works through thresholds and categories: it prohibits or restricts certain transactions that would give a country of concern, or a covered person connected to one, access to bulk sensitive personal data — including personal health data and human genomic data — above defined volumes. This article is education, not legal advice, and the thresholds and definitions are detailed. The operational point for a site is simpler: who the sponsor is, and who can reach the data the trial generates, are now compliance questions with a written record behind them, not background details.
Case by case, not a blanket restriction
The wrong responses are the two extremes. A blanket refusal of every sponsor based in a country of concern discards legitimate, well-run trials without analysis. Signing on the usual paperwork alone, without asking where the data go, ignores a rule that has been in force since 2025.
The workable position is case by case. The answer depends on the data the specific protocol generates, the systems the sponsor and its vendors use, and who can access those systems. A small imaging study with de-identified reads is a different analysis from a genomics-heavy study with biospecimens. That is why the review has to happen protocol by protocol, with counsel involved before anything is agreed — not as a site's solo judgment call, and not after signature.
The data-flow map to ask for before you sign
One document answers most of the question: a data-flow map, in writing, from the sponsor. Ask for four things:
- Hosting and storage: Which systems hold the trial data — electronic data capture (EDC), imaging, laboratory, and safety systems — and in which countries are the servers and backups located?
- Access: Who can access the data, by role and by location? Include sponsor staff, CRO staff, and every vendor and subcontractor with system access, not only the sponsor's own employees.
- Transfers: How do data move between the site, the sponsor, and vendors? Which transfers cross a border, and in what form — identified, pseudonymized, or de-identified?
- Sharing and retention: Who else receives the data, for what purpose, and how long is it retained, where, after the trial closes?
A sponsor that runs trials under this rule will have these answers ready; producing them is now ordinary diligence. A sponsor that cannot answer in writing is telling you something material about its readiness, whatever its science looks like.
Exemptions are counsel's call, not a site's assumption
The DSP contains exemptions that matter for research — including for data transactions that are part of clinical investigations regulated by the United States Food and Drug Administration (FDA), and data needed to obtain or maintain regulatory approval, generally where the data are de-identified or pseudonymized under applicable FDA regulations. Sites hear "clinical trials are exempt" and stop asking questions. That is a mistake.
An exemption is a legal conclusion about a specific transaction, with conditions and recordkeeping attached. Whether it covers your protocol, your sponsor's structure, and your vendors' access is a determination for counsel who has seen the actual data-flow map — which is one more reason to get the map first. Assume nothing, document what you relied on, and keep the correspondence. If an auditor or a sponsor's own compliance team asks later, the file should show that the site asked, in writing, before it signed.
When to pause
Pause the signature — not necessarily the relationship — when any of these appear:
- The sponsor cannot or will not provide the data-flow map in writing.
- A vendor with data access is added or changed after signing, with no updated map.
- The protocol collects genomic data or biospecimens and nobody can state, in writing, who can access them and where they are stored.
- The answers conflict across documents — the contract says one thing, the system description another.
Each pause is resolvable. Most are resolved by the sponsor completing the paperwork it should already have. A site that pauses for a written answer is not being difficult; it is doing the diligence the rule expects, and sponsors working seriously under the DSP recognize that.
The bottom line
Feasibility used to end at patients, investigators, and timelines. For sponsors based in a country of concern, it now includes a fourth question: where does the data go, and who can reach it? Ask it before signing, get the answer as a written data-flow map, and let counsel — not habit — decide what the rule requires for that protocol. That sequence protects the site, the participants whose data the trial generates, and the trial itself.
Julio G. Martinez-Clark is chief executive officer (CEO) of bioaccess\u00AE, a first-in-human contract research organization running early-phase trials anywhere from Canada down to Argentina, and of Amavita Research Services, a Miami cardiovascular research site he has operated for seven years with zero United States Food and Drug Administration (FDA) Form 483 inspection findings. He founded Global Trial Accelerators\u2122, a podcast for medtech and biotech founders navigating first-in-human studies.